Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation

Harold S Javitz, Susan M Zbikowski, Mona Deprey, Timothy A McAfee, Jennifer B McClure, Julie Richards, Sheryl L Catz, Lisa M Jack, Gary E Swan, Harold S Javitz, Susan M Zbikowski, Mona Deprey, Timothy A McAfee, Jennifer B McClure, Julie Richards, Sheryl L Catz, Lisa M Jack, Gary E Swan

Abstract

There is a lack of evidence of the relative cost-effectiveness of proactive telephone counseling (PTC) and Web-based delivery of smoking cessation services in conjunction with pharmacotherapy. We calculated the differential cost-effectiveness of three behavioral smoking cessation modalities with varenicline treatment in a randomized trial of current smokers from a large health system. Eligible participants were randomized to one of three smoking cessation interventions: Web-based counseling (n=401), PTC (n=402), or combined PTC-Web counseling (n=399). All participants received a standard 12-week course of varenicline. The primary outcome was a 7-day point prevalent nonsmoking at the 6month follow-up. The Web intervention was the least expensive followed by the PTC and PTC-Web groups. Costs per additional 6-month nonsmoker and per additional lifetime quitter were $1,278 and $2,601 for Web, $1,472 and $2,995 for PTC, and $1,617 and $3,291 for PTC-Web. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were $1,148 and $1,136 for Web, $1,320 and $1,308 for PTC, and $1,450 and $1,437 for PTC-Web. Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments. Web, PTC, and combined PTC-Web treatments were all highly cost-effective, with the Web treatment being marginally more cost-effective than the PTC or combined PTC-Web treatments.

References

    1. Fiore, M.C., et al. Treating Tobacco Use and Dependence: 2008 Update, in Clinical Practice Guideline. May 2008, U.S. Department of Health and Human Services. Public Health Service: Clinical Practice Guideline. Rockville, MD.
    1. Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Of Systematic Reviews. 2006;3:CD002850.
    1. Cobb NK, et al. Initial evaluation of a real-world Internet smoking cessation system. Nicotine & Tobacco Research. 2005;7(2):207–216. doi: 10.1080/14622200500055319.
    1. Graham AL, et al. Effectiveness of an internet-based worksite smoking cessation intervention at 12 months. Journal of Occupational and Environmental Medicine. 2007;49(8):821–828. doi: 10.1097/JOM.0b013e3180d09e6f.
    1. Saul JE, et al. Impact of a statewide Internet-based tobacco cessation intervention. Journal of Medical Internet Research. 2007;9(3):e28. doi: 10.2196/jmir.9.4.e28.
    1. Etter JF. Comparing the efficacy of two Internet-based, computer-tailored smoking cessation programs: a randomized trial. Journal of Medical Internet Research. 2005;7(1):e2. doi: 10.2196/jmir.7.1.e2.
    1. Japuntich SJ, et al. Smoking cessation via the internet: a randomized clinical trial of an internet intervention as adjuvant treatment in a smoking cessation intervention. Nicotine Tob Res. 2006;8(Suppl 1):S59–S67. doi: 10.1080/14622200601047900.
    1. Pike KJ, et al. American Cancer Society's QuitLink: randomized trial of Internet assistance. Nicotine & Tobacco Research. 2007;9(3):415–420. doi: 10.1080/14622200701188877.
    1. Strecher VJ, et al. Web-based smoking-cessation programs: results of a randomized trial. American Journal of Preventive Medicine. 2008;34(5):373–381. doi: 10.1016/j.amepre.2007.12.024.
    1. Strecher VJ, Shiffman S, West R. Randomized controlled trial of a Web-based computer-tailored smoking cessation program as a supplement to nicotine patch therapy. Addiction. 2005;100(5):682–688. doi: 10.1111/j.1360-0443.2005.01093.x.
    1. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2007;1:CD006103.
    1. Nides M, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine. 2006;166(15):1561–1568. doi: 10.1001/archinte.166.15.1561.
    1. Oncken C, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Archives of Internal Medicine. 2006;166(15):1571–1577. doi: 10.1001/archinte.166.15.1571.
    1. Niaura R, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Current Medical Research and Opinion. 2008;24(7):1931–1941. doi: 10.1185/03007990802177523.
    1. Gonzales D, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Journal of the American Medical Association. 2006;296(1):47–55. doi: 10.1001/jama.296.1.47.
    1. Jorenby DE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Journal of the American Medical Association. 2006;296(1):56–63. doi: 10.1001/jama.296.1.56.
    1. Nakamura M, et al. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics. 2007;29(6):1040–1056. doi: 10.1016/j.clinthera.2007.06.012.
    1. Tsai ST, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics. 2007;29(6):1027–1039. doi: 10.1016/j.clinthera.2007.06.011.
    1. Tonstad S, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Journal of the American Medical Association. 2006;296(1):64–71. doi: 10.1001/jama.296.1.64.
    1. Hollis JF, et al. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. Tobacco Control. 2007;16(Suppl 1):i53–i59. doi: 10.1136/tc.2006.019794.
    1. Orleans CT, et al. Self-help quit smoking interventions: effects of self-help materials, social support instructions, and telephone counseling. Journal of Consulting and Clinical Psychology. 1991;59(3):439–448. doi: 10.1037/0022-006X.59.3.439.
    1. Swan GE, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. Archives of Internal Medicine. 2003;163(19):2337–2344. doi: 10.1001/archinte.163.19.2337.
    1. Curry SJ, et al. Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organization. The New England Journal of Medicine. 1998;339(10):673–679. doi: 10.1056/NEJM199809033391006.
    1. Ringen K, et al. Smoking cessation in a blue-collar population: results from an evidence-based pilot program. American Journal of Industrial Medicine. 2002;42(5):367–377. doi: 10.1002/ajim.10129.
    1. McClure JB, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. Journal of General Internal Medicine. 2009;24(5):563–569. doi: 10.1007/s11606-009-0926-8.
    1. Swan GE, et al. Behavioral counseling and varenicline treatment for smoking cessation. American Journal of Preventive Medicine. 2010;38(5):482–490. doi: 10.1016/j.amepre.2010.01.024.
    1. Velicer WF, et al. Assessing outcome in smoking cessation studies. Psychological Bulletin. 1992;111(1):23–41. doi: 10.1037/0033-2909.111.1.23.
    1. Patrick DL, et al. The validity of self-reported smoking: a review and meta-analysis. American Journal of Public Health. 1994;84(7):1086–1093. doi: 10.2105/AJPH.84.7.1086.
    1. Gorber S, et al. The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine & Tobacco Research. 2009;11(1):12–24. doi: 10.1093/ntr/ntn010.
    1. Swan GE, et al. Cardiovascular reactivity as a predictor of relapse in male and female smokers. Health Psychology. 1993;12(6):451–458. doi: 10.1037/0278-6133.12.6.451.
    1. Garrison, G.D. and S.E. Dugan, Varenicline: a first-line treatment option for smoking cessation. Clin Ther, Mar 2009. 31(3).
    1. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. Journal of the American Medical Association. 1996;275(16):1247–1251. doi: 10.1001/jama.275.16.1247.
    1. Stapleton JA, Lowin A, Russell MA. Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness. Lancet. 1999;354(9174):210–215. doi: 10.1016/S0140-6736(99)90001-6.
    1. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tobacco Control. 2006;15:280–285. doi: 10.1136/tc.2005.015487.
    1. Javitz HS, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. American Journal of Managed Care. 2004;10(3):217–226.
    1. Wasley MA, et al. The cost-effectiveness of the nicotine transdermal patch for smoking cessation. Preventive Medicine. 1997;26(2):264–270. doi: 10.1006/pmed.1996.0127.
    1. Oster G, et al. Cost-effectiveness of nicotine gum as an adjunct to physician's advice against cigarette smoking. Journal of the American Medical Association. 1986;256(10):1315–1318. doi: 10.1001/jama.256.10.1315.
    1. Centers for Disease Control and Prevention, Smoking cessation during previous year among adults—United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep, 1993. 42: p. 504–7
    1. Croghan IT, et al. Cost-effectiveness of treating nicotine dependence: the Mayo clinic experience. Mayo Clinic Proceedings. 1997;72(10):917–924. doi: 10.4065/72.10.917.
    1. Centers for Disease Control and Prevention, Years of healthy life. Stat Notes, 1995. 7: p. 1–14.
    1. White, I.R. and J.B. Carlin, Bias and efficiency of multiple imputation compared with complete-case analysis for missing values. Stat Med (Epub ahead of print), 2010.
    1. Barnes SA, et al. Missing data assumptions and methods in smoking cessation. Addiction. 2010;105(3):431–437. doi: 10.1111/j.1360-0443.2009.02809.x.
    1. Solberg LI, et al. Repeated tobacco-use screening and intervention in clinical practice. American Journal of Preventive Medicine. 2006;31(1):62–71. doi: 10.1016/j.amepre.2006.03.013.
    1. Rogers RG, Powell-Griner E. Life expectancies of cigarette smokers and nonsmokers in the United States. Social Science & Medicine. 1991;32:1151–1159. doi: 10.1016/0277-9536(91)90092-Q.
    1. Taylor DH, et al. Benefits of smoking cessation for longevity. American Journal of Public Health. 2002;92:990–996. doi: 10.2105/AJPH.92.6.990.
    1. Centers for Disease Control and Prevention, Behavorial Risk Factor Surveillance System, in available at: . Accessed on: June 13, 2005. 2003.
    1. Wu P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health. 2006;6:300–315. doi: 10.1186/1471-2458-6-300.
    1. Bolin K, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation-results from four European countries. European Journal of Pub Health. 2009;19(6):650–654. doi: 10.1093/eurpub/ckp075.
    1. Knight HP, Boler A, Baker C. Cost-utility analysis of varenciline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497–511. doi: 10.2165/00019053-200826060-00004.
    1. Faulkner MA. Smoking cessation: an economic analysis and review of varenicline. Clinico Econ Outcomes Res. 2009;1:25–34. doi: 10.2147/CEOR.S4223.
    1. Leu RE, Schaub T. Does smoking increase medical care expenditure? Social Science & Medicine. 1983;17(23):1907–1914. doi: 10.1016/0277-9536(83)90168-5.
    1. Tengs TO, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis. 1995;15(3):369–390. doi: 10.1111/j.1539-6924.1995.tb00330.x.
    1. Cheung AM, Tsevat J. Economic evaluations of smoking interventions. Preventive Medicine. 1997;26(2):271–273. doi: 10.1006/pmed.1996.0126.
    1. Tsevat J. Impact and cost-effectiveness of smoking interventions. American Journal of Medicine. 1992;93(1A):43S–47S. doi: 10.1016/0002-9343(92)90627-N.
    1. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annual Review of Public Health. 1985;6:41–63. doi: 10.1146/annurev.pu.06.050185.000353.
    1. Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. PharmacoEconomics. 1997;11(6):538–549. doi: 10.2165/00019053-199711060-00003.
    1. Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. American Journal of Epidemiology. 1998;148:249–258.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren